Mechanistically, the study demonstrates that CLF enhances the efficacy of dual anti-PD-1 + CTLA-4 ICB by promoting a specialized CD8+ T cell population with memory potential, improving tumor eradication across various murine models. The gene discussed is CTLA4; the disease is neoplasm.